TY - JOUR
T1 - The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations
T2 - Systematic Review and Meta-Analysis
AU - Sahebkar, Amirhossein
AU - Serban, Maria Corina
AU - Penson, Peter
AU - Gurban, Camelia
AU - Ursoniu, Sorin
AU - Toth, Peter P.
AU - Jones, Steven R.
AU - Lippi, Giuseppe
AU - Kotani, Kazuhiko
AU - Kostner, Karam
AU - Rizzo, Manfredi
AU - Rysz, Jacek
AU - Banach, Maciej
AU - For The Lipid And Blood Pressure Meta-Analysis Collaboration (Lbpmc) Group
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Introduction: Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with lower circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less well studied. Aims: We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) [Lp(a)] through a meta-analysis of available randomized controlled trials (RCTs) and observational studies. Methods: This study was registered in the PROSPERO database (CRD42016036890). Scopus, MEDLINE and EMBASE were searched from inception until 22 March 2016 to identify studies investigating the effect of tamoxifen on Lp(a) values in humans. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate. Results: Meta-analysis of five studies with 215 participants suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment (SMD −0.41, 95% confidence interval −0.68 to −0.14, p = 0.003). This effect was robust in the sensitivity analysis. Conclusions: Meta-analysis suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment. Further well-designed trials are required to validate these results.
AB - Introduction: Tamoxifen is a selective estrogen receptor modulator widely used in the treatment of breast cancer. Tamoxifen therapy is associated with lower circulating low-density lipoprotein cholesterol and increased triglycerides, but its effects on other lipids are less well studied. Aims: We aimed to investigate the effect of tamoxifen on circulating concentrations of lipoprotein(a) [Lp(a)] through a meta-analysis of available randomized controlled trials (RCTs) and observational studies. Methods: This study was registered in the PROSPERO database (CRD42016036890). Scopus, MEDLINE and EMBASE were searched from inception until 22 March 2016 to identify studies investigating the effect of tamoxifen on Lp(a) values in humans. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate. Results: Meta-analysis of five studies with 215 participants suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment (SMD −0.41, 95% confidence interval −0.68 to −0.14, p = 0.003). This effect was robust in the sensitivity analysis. Conclusions: Meta-analysis suggested a statistically significant reduction of Lp(a) levels following tamoxifen treatment. Further well-designed trials are required to validate these results.
UR - http://www.scopus.com/inward/record.url?scp=85020078358&partnerID=8YFLogxK
U2 - 10.1007/s40265-017-0767-4
DO - 10.1007/s40265-017-0767-4
M3 - Review article
C2 - 28573436
AN - SCOPUS:85020078358
VL - 77
SP - 1187
EP - 1197
JO - Drugs
JF - Drugs
SN - 0012-6667
IS - 11
ER -
